Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
Clinical trial NCT04840992 · COMPLETED
Trial details
- NCT number
- NCT04840992
- Sponsor
- CanSino Biologics Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-21
- Primary completion
- 2022-07-08
- Enrollment
- 840
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.